NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Allopurinol in Depression

RecruitingPhase 2, Phase 3

Sponsor: Tanta University

Conditions: Depression

Interventions: Sertraline 50 MG, Allopurinol 300 MG

Countries: Egypt

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.

Exclusion Criteria:

Patients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment

Locations (1)

Tanta, Egypt